VAXXAS
Vaxxass is a biotechnology company that develops a novel needle-free vaccination technology. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain". Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
VAXXAS
Social Links:
Industry:
Biotechnology Health Care Medical Device
Founded:
2011-01-01
Address:
Brisbane, Queensland, Australia
Country:
Australia
Website Url:
http://www.vaxxas.com
Total Employee:
51+
Status:
Active
Contact:
61282057379
Total Funding:
102.51 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager Google Analytics Google Maps Content Delivery Network
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
Integral Molecular
Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies
Osciflex
Osciflex system imitates nature’s process to prevent deadly blood clots.
Pleno
Pleno is a biotechnology company that aims speeding up disease diagnosis and treatment.
Quantitative Radiology Solutions
Quantitative Radiology Solutions offers advanced body-wide quantification of medical images.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Strados Labs
Strados Labs innovates respiratory monitoring using smart biosensors and artificial intelligence.
Current Advisors List
Current Employees Featured
Founder
Investors List
Wellcome Trust
Wellcome Trust investment in Grant - Vaxxas
UniQuest
UniQuest investment in Series C - Vaxxas
OneVentures
OneVentures investment in Series C - Vaxxas
Australian Government
Australian Government investment in Grant - Vaxxas
Australian Government
Australian Government investment in Grant - Vaxxas
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - Vaxxas
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Vaxxas
OneVentures
OneVentures investment in Series B - Vaxxas
HealthCare Ventures
HealthCare Ventures investment in Series B - Vaxxas
OneVentures
OneVentures investment in Series A - Vaxxas
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-01 | Vaxxas Appoints Doug Cubbin as Chief Financial Officer |
| 2022-04-13 | Vaxxas Announces Appointment of Dan Devine as Chief Business Officer and General Counsel |
Official Site Inspections
http://www.vaxxas.com Semrush global rank: 8.9 M Semrush visits lastest month: 454
- Host name: syn112.syd4.hostyourservices.net
- IP address: 43.250.140.38
- Location: Australia
- Latitude: -33.494
- Longitude: 143.2104
- Timezone: Australia/Sydney
More informations about "Vaxxas"
About - Vaxxas
Vaxxas is targeting initial applications in infectious disease and oncology and has forged collaborations with leading global organizations in vaccine commercialization, including Merck/MSD, the United States Biomedical …See details»
Vaxxas - Crunchbase Company Profile & Funding
Organization. Vaxxas . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Vaxxas closed its last funding round on Aug 23, 2023 from a Grant round. Who are Vaxxas 's …See details»
Vaxxas Company Profile 2025: Valuation, Funding & Investors
Vaxxas General Information Description. Developer of a needle-free vaccine delivery system designed to revolutionize the global delivery of vaccines. The company's system consists of an …See details»
Vaxxas - LinkedIn
Vaxxas CEO and President David Hoey is honoured to have received the Award for Excellence in Biotechnology at last night’s AmCham Australia Gala 🏆 The AmCham Alliance Awards were established ...See details»
Vaxxas: Making needle-free vaccination a reality on a …
— Dr Angus Forster, Chief Development and Operating Officer, Vaxxas . SIEF Ross Metcalf STEM+ Business Fellowship program has exceeded my expectations. My aim with this program was to achieve experience with …See details»
Vaxxas Named Stage Winner of United States’ BARDA …
4 days ago - The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...See details»
Vaxxas granted licence to develop new needle-free vaccine
Oct 29, 2024 Brisbane-based vaccine patch company Vaxxas is developing the first room temperature-stable needleless vaccine for one of the world’s most common cold-like diseases, …See details»
Vaxxas secures $3.2m from US for COVID patch project
4 days ago Vaxxas, a Brisbane-based clinical-stage biotechnology company commercialising a needle-free vaccination platform, has secured $3.2 million from the United States Biomedical …See details»
Vaxxas Named Stage Winner of United States’ BARDA Prize to …
4 days ago Vaxxas will collaborate with The University of Queensland’s world-leading mRNA research and manufacturing BASE facility, a co-applicant on Vaxxas’ application, to advance …See details»
UQ congratulates Vaxxas on $30m partnership
Oct 14, 2020 “The success of Vaxxas is creating jobs as part of the innovation economy, and could improve the distribution and safety of vaccines globally,” Professor Rowan said. ... The …See details»
Vaxxas - BIO International Convention 2025
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD …See details»
Precinct Partner - Vaxxas | Northshore Brisbane
Australian biotechnology company Vaxxas, is poised to transform the way vaccines are delivered globally from its new Northshore Brisbane headquarters and manufacturing facility with …See details»
VAXXAS INC. Company Profile | Cambridge, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for VAXXAS INC. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Coming in from the cold: needle-free patch technology for mRNA …
Jan 17, 2023 David Hoey, Vaxxas Chief Executive Officer, said: "Earning this significant funding from one of the world leaders in vaccine development is a great honor, and validates the …See details»
Invention driving needle-free vaccine delivery | Translational …
The first was an US$12 million investment injection by the global pharmaceutical company, Merck – a partner to Vaxxas since 2012 – for the use of Vaxxas’ patch with an undisclosed vaccine. …See details»
VAXXAS PTY LTD Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for VAXXAS PTY LTD of HAMILTON, QUEENSLAND. Get the latest business insights from Dun & Bradstreet.See details»
Vaxxas - BIO International Convention | BIO
Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... During this …See details»
SK bioscience and Vaxxas Enter Joint Development Agreement for …
Aug 24, 2023 SK bioscience and Vaxxas have officially entered into a Joint Development Agreement. This collaboration is set to revolutionize vaccine delivery by developing a novel …See details»
Vaxxas Pty Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Vaxxas Pty Ltd. with its drug pipeline, therapeutic area, technology platform, 10 clinical trials, 19 news, and 19 literature, Disease Domain:Infectious Diseases, Technology …See details»
Vaxxas announces CEPI partnership to advance needle-free mRNA …
Jan 19, 2023 Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the …See details»